Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Mar 29;3(3):CD011498.
doi: 10.1002/14651858.CD011498.pub2.

Non-surgical versus surgical treatment for oesophageal cancer

Lawrence M J Best  1 , Muntzer Mughal, Kurinchi Selvan Gurusamy
Affiliations
Meta-Analysis

Non-surgical versus surgical treatment for oesophageal cancer

Lawrence M J Best et al. Cochrane Database Syst Rev. .

Abstract

Background: Oesophageal cancer is the sixth most common cause of cancer-related mortality in the world. Currently surgery is the recommended treatment modality when possible. However, it is unclear whether non-surgical treatment options is equivalent to oesophagectomy in terms of survival.

Objectives: To assess the benefits and harms of non-surgical treatment versus oesophagectomy for people with oesophageal cancer.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Science Citation Index, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) up to 4th March 2016. We also screened reference lists of included studies.

Selection criteria: Two review authors independently screened all titles and abstracts of articles obtained from the literature searches and selected references for further assessment. For these selected references, we based trial inclusion on assessment of the full-text articles.

Data collection and analysis: Two review authors independently extracted study data. We calculated the risk ratio (RR) with 95% confidence interval (CI) for binary outcomes, the mean difference (MD) or the standardised mean difference (SMD) with 95% CI for continuous outcomes, and the hazard ratio (HR) for time-to-event outcomes. We performed meta-analyses where it was meaningful.

Main results: Eight trials, which included 1132 participants in total, met the inclusion criteria of this Cochrane review. These trials were at high risk of bias trials. One trial (which included five participants) did not contribute any data to this Cochrane review, and we excluded 13 participants in the remaining trials after randomisation; this left a total of 1114 participants, 510 randomised to non-surgical treatment and 604 to surgical treatment for analysis. The non-surgical treatment was definitive chemoradiotherapy in five trials and definitive radiotherapy in three trials. All participants were suitable for major surgery. Most of the data were from trials that compared chemoradiotherapy with surgery. There was no difference in long-term mortality between chemoradiotherapy and surgery (HR 0.88, 95% CI 0.76 to 1.03; 602 participants; four studies; low quality evidence). The long-term mortality was higher in radiotherapy than surgery (HR 1.39, 95% CI 1.18 to 1.64; 512 participants; three studies; very low quality evidence). There was no difference in long-term recurrence between non-surgical treatment and surgery (HR 0.96, 95% CI 0.80 to 1.16; 349 participants; two studies; low quality evidence). The difference between non-surgical and surgical treatments was imprecise for short-term mortality (RR 0.39, 95% CI 0.11 to 1.35; 689 participants; five studies; very low quality evidence), the proportion of participants with serious adverse in three months (RR 0.61, 95% CI 0.25 to 1.47; 80 participants; one study; very low quality evidence), and proportion of people with local recurrence at maximal follow-up (RR 0.89, 95% CI 0.70 to 1.12; 449 participants; three studies; very low quality evidence). The health-related quality of life was higher in non-surgical treatment between four weeks and three months after treatment (Spitzer Quality of Life Index; MD 0.93, 95% CI 0.24 to 1.62; 165 participants; one study; very low quality evidence). The difference between non-surgical and surgical treatments was imprecise for medium-term health-related quality of life (three months to two years after treatment) (Spitzer Quality of Life Index; MD -0.95, 95% CI -2.10 to 0.20; 62 participants; one study; very low quality of evidence). The proportion of people with dysphagia at the last follow-up visit prior to death was higher with definitive chemoradiotherapy compared to surgical treatment (RR 1.48, 95% CI 1.01 to 2.19; 139 participants; one study; very low quality evidence).

Authors' conclusions: Based on low quality evidence, chemoradiotherapy appears to be at least equivalent to surgery in terms of short-term and long-term survival in people with oesophageal cancer (squamous cell carcinoma type) who are fit for surgery and are responsive to induction chemoradiotherapy. However, there is uncertainty in the comparison of definitive chemoradiotherapy versus surgery for oesophageal cancer (adenocarcinoma type) and we cannot rule out significant benefits or harms of definitive chemoradiotherapy versus surgery. Based on very low quality evidence, the proportion of people with dysphagia at the last follow-up visit prior to death was higher with definitive chemoradiotherapy compared to surgery. Based on very low quality evidence, radiotherapy results in less long-term survival than surgery in people with oesophageal cancer who are fit for surgery. However, there is a risk of bias and random errors in these results, although the risk of bias in the studies included in this systematic review is likely to be lower than in non-randomised studies.Further trials at low risk of bias are necessary. Such trials need to compare endoscopic treatment with surgical treatment in early stage oesophageal cancer (carcinoma in situ and Stage Ia), and definitive chemoradiotherapy with surgical treatments in other stages of oesophageal cancer, and should measure and report patient-oriented outcomes. Early identification of responders to chemoradiotherapy and better second-line treatment for non-responders will also increase the need and acceptability of trials that compare definitive chemoradiotherapy with surgery.

PubMed Disclaimer

Conflict of interest statement

This report is independent research and is funded by the National Institute for Health Research (NIHR Cochrane Programme Grants, 13/89/03 ‐ Evidence‐based diagnosis and management of upper digestive, hepato‐biliary, and pancreatic disorders). The views expressed in this publication are those of the review authors and not necessarily those of the NHS, the National Institute for Health Research, or the Department of Health.

Figures

1
1
Study flow diagram.
2
2
'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies.
3
3
'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study.
1.1
1.1. Analysis
Comparison 1 Surgical versus non‐surgical treatment of oesophageal cancer, Outcome 1 Short‐term mortality.
1.2
1.2. Analysis
Comparison 1 Surgical versus non‐surgical treatment of oesophageal cancer, Outcome 2 Long‐term mortality (binary).
1.3
1.3. Analysis
Comparison 1 Surgical versus non‐surgical treatment of oesophageal cancer, Outcome 3 Long‐term mortality (time‐to‐event).
1.4
1.4. Analysis
Comparison 1 Surgical versus non‐surgical treatment of oesophageal cancer, Outcome 4 Proportion with a serious adverse event within 3 months.
1.5
1.5. Analysis
Comparison 1 Surgical versus non‐surgical treatment of oesophageal cancer, Outcome 5 Short‐term health‐related quality of life.
1.6
1.6. Analysis
Comparison 1 Surgical versus non‐surgical treatment of oesophageal cancer, Outcome 6 Medium‐term health‐related quality of life.
1.7
1.7. Analysis
Comparison 1 Surgical versus non‐surgical treatment of oesophageal cancer, Outcome 7 Long‐term recurrence (binary).
1.8
1.8. Analysis
Comparison 1 Surgical versus non‐surgical treatment of oesophageal cancer, Outcome 8 Long‐term recurrence (time‐to‐event).
1.9
1.9. Analysis
Comparison 1 Surgical versus non‐surgical treatment of oesophageal cancer, Outcome 9 Local recurrence (binary).
1.10
1.10. Analysis
Comparison 1 Surgical versus non‐surgical treatment of oesophageal cancer, Outcome 10 Proportion with any adverse event within 3 months.
1.11
1.11. Analysis
Comparison 1 Surgical versus non‐surgical treatment of oesophageal cancer, Outcome 11 Length of hospital stay (days).
1.12
1.12. Analysis
Comparison 1 Surgical versus non‐surgical treatment of oesophageal cancer, Outcome 12 Dysphagia at maximal follow‐up.
1.13
1.13. Analysis
Comparison 1 Surgical versus non‐surgical treatment of oesophageal cancer, Outcome 13 Long‐term mortality (time‐to‐event): stratified by treatment.
1.14
1.14. Analysis
Comparison 1 Surgical versus non‐surgical treatment of oesophageal cancer, Outcome 14 Long‐term mortality (binary): definitive chemoradiotherapy versus surgery with neoadjuvant chemotherapy.
1.15
1.15. Analysis
Comparison 1 Surgical versus non‐surgical treatment of oesophageal cancer, Outcome 15 Long‐term mortality (time‐to‐event): definitive chemoradiotherapy versus surgery with neoadjuvant chemotherapy or chemoradiotherapy.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Badwe 1999 {published data only}
    1. Badwe RA, Sharma V, Bhansali MS, Dinshaw KA, Patil PK, Dalvi N, et al. The quality of swallowing for patients with operable esophageal carcinoma: a randomized trial comparing surgery with radiotherapy. Cancer 1999;85(4):763‐8. - PubMed
Bedenne 2007 {published data only}
    1. Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. Journal of Clinical Oncology 2007;25(10):1160‐8. - PubMed
    1. Bedenne L, Michel P, Bouché O, Triboulet JP, Conroy T, Pezet D, et al. Randomized phase III trial in locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102). Proceedings of the American Society of Clinical Oncology 2002;21(1):130.
    1. Bonnetain F, Bedenne L, Michel P, Bouche O, Triboulet JP, Conroy T, et al. Definitive results of a comparative longitudinal quality of life study using the Spitzer index in the randomized multicentric phase III trial FFCD 9102 (surgery vs radiochemotherapy in patients with locally advanced esophageal cancer). Proceedings of the American Society of Clinical Oncology 2003;39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL:250.
    1. Bonnetain F, Bouché O, Michel P, Mariette C, Conroy T, Pezet D, et al. A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer. Annals of Oncology 2006;17(5):827‐34. - PubMed
Blazeby 2014 {published data only}
    1. Blazeby JM, Strong S, Donovan JL, Wilson C, Hollingworth W, Crosby T, et al. Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancer. British Journal of Cancer 2014;111(2):234‐40. - PMC - PubMed
Carstens 2007 {published and unpublished data}
    1. Carstens H, Albertsson M, Friesland S, Adell G, Frykholm G, Wagenius G, et al. A randomized trial of chemoradiotherapy versus surgery alone in patients with resectable esophageal cancer. Journal of Clinical Oncology 2007;25(18 Suppl 1):4530.
Chiu 2005 {published data only}
    1. Chan AC, Lee DW, Leung SF, Griffith J, Siu WT, Li MK, et al. A multi‐center randomized controlled trial comparing standard esophagectomy versus primary chemo‐irradiation as the treatment for squamous esophageal cancer ‐ early results. Gastroenterology 2003;124(4):A298‐9.
    1. Chiu PW, Cheung FK, Mui WL, Yung MY, Lam CC, Chan AC, et al. The effect of definitive chemoradiotherapy (ChemoRT) against esophagectomy on pulmonary function in patients with squamous esophageal cancer ‐ results from a prospective randomized trial by Chinese University research group for esophageal cancer (CURE). Gastroenterology 2006;130(4):A454‐5.
    1. Chiu PWY, Chan ACW, Leung SF, Leong HT, Kwong KH, Li MKW, et al. Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). Journal of Gastrointestinal Surgery 2005;9(6):794‐802. - PubMed
    1. Teoh AYB, Chiu PWY, Yeung WK, Liu SYW, Wong SKH, Ng EKW. Long‐term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial. Annals of Oncology 2013;24(1):165‐71. - PubMed
Fok 1994 {published data only}
    1. Fok M, Sham JST, Choy D, Cheng SWK, Wong J. Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery 1994;113(2):138‐47. - PubMed
Stahl 2005 {published data only}
    1. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. Journal of Clinical Oncology 2005;23(10):2310‐7. - PubMed
    1. Stahl M, Wilke H, Lehmann N, Stuschke M, German Oesophageal Cancer Study Group. Long‐term results of a phase III study investigating chemoradiation with and without surgery in locally advanced squamous cell carcinoma (LA‐SCC) of the esophagus. Journal of Clinical Oncology 2008;26(15 Suppl 1):4530.
    1. Stahl M, Wilke H, Preusser P, Stuschke M, Walz MK, Betzler M, et al. Preoperative chemoradiation followed by surgery versus definitive chemoradiation without surgery in the treatment of patients with locally advanced squamous cell carcinoma (LA‐SCC) of the esophagus: first report of a German multicenter study. Proceedings of the American Society of Clinical Oncology 2001;20:163.
    1. Stahl M, Wilke H, Walz MK, Seeber S, Klump B, Budach W, et al. Randomized phase III trial in locally advanced squamous cell carcinoma (SCC) of the esophagus: chemoradiation with and without surgery [abstract]. Proceedings of the American Society of Clinical Oncology 2003;39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31‐June 3, 2003:Abstract No. 1001.
    1. Stuschke M, Stahl M, Wilke H, Walz M, Seeber S, Klump B, et al. Randomized phase III trial in locally advanced squamous cell carcinoma of the esophagus: neoadjuvant radiochemotherapy followed by surgery vs. definitive radiochemotherapy. Radiotherapy and Oncology 2004;73 Suppl 1:148.
Sun 2006 {published data only}
    1. Sun XD, Yu JM, Fan XL, Ren RM, Li MH, Zhang GL. Randomized clinical study of surgery versus radiotherapy alone in the treatment of resectable esophageal cancer in the chest. Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology] 2006;28(10):784‐7. - PubMed
    1. Yu J, Ren R, Sun X, Yin Y, Fu Z. A randomized clinical study of surgery versus radiotherapy in the treatment of resectable esophageal cancer. Journal of Clinical Oncology 2006;24(18 Suppl 1):4013. - PubMed

References to studies excluded from this review

Desai 1987 {published data only}
    1. Desai PB, Advani SH, Sharma S, Saikia T, Gopal R. A comparison of surgery, radiotherapy and combination chemotherapy (followed by radiotherapy or surgery) in the treatment of locally advanced esophageal carcinoma. Proceedings of the American Society of Clinical Oncology. 1987:Abstract 289.
Earlam 1991 {published data only}
    1. Earlam R. An MRC prospective randomised trial of radiotherapy versus surgery for operable squamous cell carcinoma of the oesophagus. Annals of the Royal College of Surgeons of England 1991;73(1):8‐12. - PMC - PubMed
Hainsworth 2007 {published data only}
    1. Gray JR, Hainsworth JD, Meluch AA, Spigel DR, Rosenoff SH, Bradof JE, et al. Concurrent paclitaxel/carboplatin/infusional 5‐FU/radiation therapy (RT) with or without subsequent esophageal resection in patients with localized esophageal cancer: A Minnie Pearl Cancer Research Network trial. Journal of Clinical Oncology 2005;23(16 Suppl 1):4018.
    1. Hainsworth JD, Meluch AA, Gray JR, Spigel DR, Meng C, Bearden JD, et al. Concurrent chemoradiation followed by esophageal resection vs chemoradiation alone for localized esophageal cancer. Community Oncology 2007;4(7):431‐9.
Ilson 2007 {published data only}
    1. Ilson DH. Surgery after primary chemoradiotherapy in squamous cancer of the esophagus: is the photon mightier than the sword?. Journal of Clinical Oncology 2007;25(10):1155‐6. - PubMed
Nozaki 2014 {published data only}
    1. Nozaki I, Kato K, Igaki H, Ito Y, Daiko H, Yano M, et al. Safety profile of thoracoscopic esophagectomy for esophageal cancer compared with traditional thoracotomy from the results of JCOG0502: a randomized trial of esophagectomy versus chemoradiotherapy. Journal of Clinical Oncology 2014;32(1 Suppl 3):Abstract 82.

Additional references

Ajani 2011
    1. Ajani J, Barthel JS, Bentrem DJ, D'Amico T, Das P, Denlinger CS, et al. Esophageal and esophagogastric junction cancers. Journal of the National Comprehensive Cancer Network 2011;9(8):830‐87. - PubMed
AJCC Cancer Staging Manual 2010
    1. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th Edition. New York: Springer, 2010.
ASA 2014
    1. American Society of Anaesthesiologists. ASA physical status classification system. https://www.asahq.org/clinical/physicalstatus.htm (accessed 14 September 2014).
Berry 2014
    1. Berry M. Esophageal cancer: staging system and guidelines for staging and treatment. Journal of Thoracic Disease 2014;6 Suppl 3:289‐97. - PMC - PubMed
CONSORT 2010
    1. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine 2010;152(11):726‐32. - PubMed
Cuschieri 1992
    1. Cuschieri A, Shimi S, Banting S. Endoscopic oesophagectomy through a right thoracoscopic approach. Journal of the Royal College of Surgeons of Edinburgh 1992;37(1):7‐11. - PubMed
Demets 1987
    1. Demets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341‐50. - PubMed
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177‐88. - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐34. - PMC - PubMed
FDA 2006
    1. Center for Biologics Evaluation and Research, U.S. Food, Drug Administration. Guidance for industry. Adverse reactions section of labeling for human prescription drug and biological products — content and format. January 2006. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati... (accessed on 4 July 2014).
Goh 2015
    1. Goh SL, Silva RP, Dhital K, Gett RM. Is low serum albumin associated with postoperative complications in patients undergoing oesophagectomy for oesophageal malignancies?. Interactive Cardiovascular and Thoracic Surgery 2015;20(1):107‐13. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. Chichester: John Wiley & Sons.
IARC 2014
    1. International Agency for Research on Cancer. GLOBOCAN 2012. http://globocan.iarc.fr/Default.aspx 2014 (accessed 5 September 2014).
ICH‐GCP 1996
    1. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Code of Federal Regulation & ICH Guidelines. Media: Parexel Barnett, 1996.
Ishihara 2008
    1. Ishihara R, Iishi H, Uedo N, Takeuchi Y, Yamamoto S, Yamada T, et al. Comparison of EMR and endoscopic submucosal dissection for en bloc resection of early esophageal cancers in Japan. Gastrointestinal Endoscopy 2008;68(6):1066‐72. - PubMed
Luketich 2000
    1. Luketich JD, Schauer PR, Christie NA, Weigel TL, Raja S, Fernando HC, et al. Minimally invasive esophagectomy. Annals of Thoracic Surgery 2000;70(3):906‐11; discussion 911‐2. - PubMed
McKeown 1976
    1. McKeown KC. Total three‐stage oesophagectomy for cancer of the oesophagus. The British Journal of Surgery 1976;63(4):259‐62. - PubMed
MHRA 2013
    1. Medicines and Healthcare products Regulatory Agency (MHRA). Clinical trials for medicines: Safety reporting ‐ SUSARs and DSURs. 2013. http://www.mhra.gov.uk/Howweregulate/Medicines/Licensingofmedicines/Clin... (accessed on 4 July 2014).
Migliore 2007
    1. Migliore M, Choong C, Lim E, Goldsmith K, Ritchie A, Wells F. A surgeon's case volume of oesophagectomy for cancer strongly influences the operative mortality rate. European Journal of Cardio‐Thoracic Surgery 2007;32(2):375‐80. - PubMed
Orringer 1978
    1. Orringer MB, Sloan H. Esophagectomy without thoracotomy. Journal of Thoracic and Cardiovascular Surgery 1978;76(5):643‐54. - PubMed
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34. - PubMed
Pennathur 2013
    1. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. The Lancet 2013;381(9864):400‐12. - PubMed
Pöttgen 2012
    1. Pöttgen C, Stuschke M. Radiotherapy versus surgery within multimodality protocols for esophageal cancer‐‐a meta‐analysis of the randomized trials. Cancer Treatment Reviews 2012;38(6):599‐604. - PubMed
Review Manager 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (Revman). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rice 2010
    1. Rice TW, Blackstone EG, Rusch VW. 7th edition of the AJCC cancer staging manual: esophagus and esophagogastric junction. Annals of Surgical Oncology 2010;17(7):1721‐4. - PubMed
Sjoquist 2011
    1. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta‐analysis. The Lancet Oncology 2011;12(7):681‐92. - PubMed
SPIRIT 2013
    1. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža‐Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Annals of Internal Medicine 2013;158(3):200‐7. - PMC - PubMed
Spitzer 1981
    1. Spitzer WO, Dobson AJ, Hall J, Chesterman E, Levi J, Shepherd R, et al. Measuring the quality of life of cancer patients: a concise QL‐index for use by physicians. Journal of Chronic Diseases 1981;34(12):585‐97. - PubMed
Stahl 2013
    1. Stahl M, Mariette C, Haustermans K, Cervantes A, Arnold D, EMSO Guidelines Working Group. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Annals of Oncology 2013;24(Suppl 6):vi51‐6. - PubMed
Sun 2014
    1. Sun F, Yuan P, Chen T, Hu J. Efficacy and complication of endoscopic submucosal dissection for superficial esophageal carcinoma: a systematic review and meta‐analysis. Journal of Cardiothoracic Surgery 2014;9:78. - PMC - PubMed
van Hagen 2012
    1. Hagen P, Hulshof MCMM, Lanschot JJB, Steyerberg EW, Berge Henegouwen MI, Wijnhoven BPL, et al. the CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. The New England Journal of Medicine 2012;366(22):2074‐84. - PubMed
Yamamoto 2013
    1. Yamamoto M, Weber JM, Karl RC, Meredith KL. Minimally invasive surgery for esophageal cancer: review of the literature and institutional experience. Cancer Control 2013;20(2):130‐7. - PubMed
Yamashita 2008
    1. Yamashita H, Nakagawa K, Yamada K, Kaminishi M, Mafune K, Ohtomo K. A single institutional non‐randomized retrospective comparison between definitive chemoradiotherapy and radical surgery in 82 Japanese patients with resectable esophageal squamous cell carcinoma. Diseases of the Esophagus 2008;21(5):430‐6. - PubMed

References to other published versions of this review

Best 2015
    1. Best LMJ, Gurusamy KS. Surgical versus non‐surgical treatment for oesophageal cancer. Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD011498] - DOI - PMC - PubMed

Publication types

LinkOut - more resources